We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

498 hedge funds and large institutions have $22.6B invested in Alnylam Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 96 funds opening new positions, 167 increasing their positions, 160 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 44

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

10% more funds holding

Funds holding: 452 → 498 (+46)

8% more capital invested

Capital invested by funds: $20.9B → $22.6B (+$1.71B)

4% more repeat investments, than reductions

Existing positions increased: 167 | Existing positions reduced: 160

0.29% less ownership

Funds ownership: 94.23% → 93.94% (-0.29%)

17% less call options, than puts

Call options by funds: $267M | Put options by funds: $321M

Holders
498
Holders Change
+46
Holders Change %
+10.18%
% of All Funds
7.26%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
96
Increased
167
Reduced
160
Closed
44
Calls
$267M
Puts
$321M
Net Calls
-$54.7M
Net Calls Change
-$24.4M

Top Buyers

1
Norges Bank
Norges Bank
Norway
+$144M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$133M
3
Capital International Investors
Capital International Investors
California
+$83.3M
4
Morgan Stanley
Morgan Stanley
New York
+$68.8M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$48.9M

Top Sellers

1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$204M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$165M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$98.1M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$75.1M
5
Capital World Investors
Capital World Investors
California
-$60.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
MML Investors Services
276
MML Investors Services
Massachusetts
$756K +$161K +947 +32%
PRC
277
Pearl River Capital
Michigan
$742K +$660K +3,876 New
SAM
278
Shell Asset Management
Netherlands
$728K -$176K -1,031 -21%
BAMF
279
BI Asset Management Fondsmaeglerselskab
Denmark
$721K +$354K +2,076 +123%
ERSOT
280
Employees Retirement System of Texas
Texas
$720K +$641K +3,761 New
BMSSC
281
B. Metzler seel. Sohn & Co
Germany
$714K – – –
OCM
282
Orion Capital Management
California
$703K – – –
Osaic Holdings
283
Osaic Holdings
Arizona
$688K -$106K -625 -15%
TMAM
284
Tokio Marine Asset Management
Japan
$684K +$33.2K +195 +6%
SMH
285
Sanders Morris Harris
Texas
$684K – – –
SPAS
286
Spectrum Planning & Advisory Services
California
$681K – – –
CWM
287
CIBC World Markets
New York
$666K +$593K +3,482 New
SLAM
288
Swiss Life Asset Management
$654K -$133K -778 -19%
EFM
289
E Fund Management
China
$639K +$182K +1,069 +47%
NPT
290
Nixon Peabody Trust
Massachusetts
$632K +$307K +1,800 +120%
MAP
291
Moody Aldrich Partners
Massachusetts
$629K +$171K +1,002 +44%
LJHT
292
Laurie J. Hall Trustee
$622K – – –
DADC
293
D.A. Davidson & Co
Montana
$593K -$32.7K -192 -6%
OAM
294
Oxford Asset Management
United Kingdom
$586K +$522K +3,064 New
WEG
295
World Equity Group
Illinois
$577K -$64.7K -380 -11%
AIM
296
Aquila Investment Management
New York
$574K +$170K +1,000 +50%
NIM
297
NEOS Investment Management
Connecticut
$572K +$509K +2,989 New
RIA
298
Regal Investment Advisors
Michigan
$568K +$27.6K +162 +6%
SFA
299
Souders Financial Advisors
Ohio
$564K +$43.4K +255 +9%
Wolverine Trading
300
Wolverine Trading
Illinois
$564K +$502K +2,946 New
10 11
12
13 14

ALNY Hedge Fund Activity: Q4 2023 in Review

498 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2023, worth a combined $22.6B — up 8.2% from $20.9B a quarter earlier.

Buyers outnumbered sellers: 96 funds opened new ALNY positions and 44 closed out — a net gain of 52 holders — while 167 added to existing stakes and 160 trimmed.

The largest buyer was Norges Bank, adding an estimated $144M. The largest seller was Baillie Gifford & Co, cutting an estimated $204M.

  • 498 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2023, up from 452 in Q3 2023.
  • Funds reported $22.6B of Alnylam Pharmaceuticals stock for Q4 2023, up 8.2% quarter-over-quarter.
  • 96 funds opened new Alnylam Pharmaceuticals positions in Q4 2023 and 44 closed out, a net change of +52 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q4 2023 was Norges Bank, an estimated $144M added.
  • The largest Alnylam Pharmaceuticals seller in Q4 2023 was Baillie Gifford & Co, an estimated $204M sold.

Based on aggregated 13F filings for Q4 2023.